Your browser doesn't support javascript.
loading
Prognostic Value of Repeat Hepatectomy for Hepatocellular Carcinoma Patients.
Nanashima, Atsushi; Tanoue, Yukinori; Hiyoshi, Masahide; Imamura, Naoya; Yano, Koichi; Hamada, Takeomi; Kitamura, Eiji; Kai, Kengo; Tahira, Kousei; Nagayasu, Takeshi.
Affiliation
  • Nanashima A; Division of Hepatobiliary Pancreatic Surgery, Department of Surgery, University of Miyazaki Faculty of Medicine, Miyazaki, Japan; a_nanashima@med.miyazaki-u.ac.jp.
  • Tanoue Y; Division of Surgical Oncology and Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
  • Hiyoshi M; Division of Hepatobiliary Pancreatic Surgery, Department of Surgery, University of Miyazaki Faculty of Medicine, Miyazaki, Japan.
  • Imamura N; Division of Hepatobiliary Pancreatic Surgery, Department of Surgery, University of Miyazaki Faculty of Medicine, Miyazaki, Japan.
  • Yano K; Division of Hepatobiliary Pancreatic Surgery, Department of Surgery, University of Miyazaki Faculty of Medicine, Miyazaki, Japan.
  • Hamada T; Division of Hepatobiliary Pancreatic Surgery, Department of Surgery, University of Miyazaki Faculty of Medicine, Miyazaki, Japan.
  • Kitamura E; Division of Hepatobiliary Pancreatic Surgery, Department of Surgery, University of Miyazaki Faculty of Medicine, Miyazaki, Japan.
  • Kai K; Division of Hepatobiliary Pancreatic Surgery, Department of Surgery, University of Miyazaki Faculty of Medicine, Miyazaki, Japan.
  • Tahira K; Division of Hepatobiliary Pancreatic Surgery, Department of Surgery, University of Miyazaki Faculty of Medicine, Miyazaki, Japan.
  • Nagayasu T; Division of Surgical Oncology and Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Anticancer Res ; 42(9): 4553-4561, 2022 Sep.
Article in En | MEDLINE | ID: mdl-36039454
ABSTRACT
BACKGROUND/

AIM:

The potential for repeat hepatectomy has been increasing in hepatocellular carcinoma (HCC) patients. PATIENTS AND

METHODS:

To assess its significance, we examined the clinical features, surgical records, and survival of 279 HCC patients who underwent hepatectomy as primary treatment. Patients were divided into three groups single hepatectomy without HCC relapse in 97 patients (Group 1), single hepatectomy with HCC relapse in 133 patients (Group 2) and repeat hepatectomy for HCC relapse in 49 patients (Group 3). Group 3 was divided into three subgroups. Multiple, larger size (>5 cm), and confluent nodular HCC.

RESULTS:

Child-Pugh B patients were significantly higher in Group 2 (p<0.01). The prevalence of histological vascular involvement was significantly higher in Group 2 than in the other groups (p<0.01). Although Group 2 showed significantly poorer survival (p<0.01), the 10-year overall survival in Groups 1 and 3 was over 70% but not different between groups. The relapse-free survival period was significantly correlated with overall survival, and patients with a cancer-free period of over 36 months showed significantly better 10-year survival rates than those with a period of less than 36 months (p<0.01). Patients undergoing 3 or more repeat hepatectomies also showed good survival periods.

CONCLUSION:

Careful follow-up and proper decision-making in terms of repeat hepatectomy with multimodal treatments including novel chemotherapies upon assessment of postoperative tumor relapse are important in HCC patients to prolong survival.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Hepatocellular / Liver Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Anticancer Res Year: 2022 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Hepatocellular / Liver Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Anticancer Res Year: 2022 Document type: Article
...